Nilotinib Heumann (Nilotinib)

Nilotinib is a targeted tyrosine‑kinase inhibitor used in hematologic malignancies that express the BCR‑ABL fusion protein.

• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival.
• Accelerated or blast phase CML: provides disease control in advanced disease stages.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: contributes to remission induction and disease management.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase as well as related kinases such as c‑KIT and PDGFR. By blocking these enzymes, it prevents downstream signaling that drives uncontrolled proliferation of leukemic cells, leading to cell cycle arrest and apoptosis of malignant clones.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Rash: skin erythema or pruritus.
• Fatigue: generalized tiredness.
• Headache: mild to moderate intensity.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusion or ischemia.
• QT interval prolongation: risk of ventricular arrhythmias.
• Severe liver injury: marked elevation of transaminases.
• Pancreatitis: abdominal pain with elevated enzymes.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hematologic abnormalities: thrombocytopenia or neutropenia.

When prescribing Nilotinib, clinicians should observe several safety measures.

• Cardiac monitoring: assess baseline ECG and monitor QT interval.
• Liver function: check hepatic enzymes before and during therapy.
• Glucose control: monitor blood glucose in diabetic patients.
• Drug interactions: avoid strong CYP3A4 inhibitors and QT‑prolonging agents.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nilotinib interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib levels.
• QT‑prolonging drugs (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmia.
• Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower drug exposure.
• Warfarin: monitor INR as Nilotinib may affect anticoagulation.